VON WILLEBRAND DISEASE PROPHYLAXIS NETWORK (vWD PN) The VWD International Prophylaxis (VIP) Study - VIP-study

Von Willebrand disease prophylaxis network0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•A. Type 1: eligible for participation if
•1. < or = 20% RCo and/or < or = 20% FVIII; and
•2. DDAVP non-responsive, defined as occurrence of bleeding episodes not responding satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator; and
•3. Bleeding indication criteria are met (page 9-11 protocol) . ;B. Type 2: eligible for participation if
•1. DDAVP non-responsive, defined as occurrence of bleeding episodes not responding satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator; or Type 2B; and
•2. Bleeding indication criteria are met (page 9-11 protocol) ;C. Type 3: eligible for participation if
•1. Bleeding indication criteria are met (page 9-11 protocol)

•A. They have acquired VWD;B. They have a history of inhibitory antibodies to VWF;C. They are already on prophylaxis, defined as receiving factor infusions at least once per week to prevent or decrease the severity of bleeding with the intention of maintaining this regimen for, on average, 45 or more weeks per year; or are receiving factor infusions on a regular basis to prevent or decrease the severity of menorrhagia.

发起方

Von Willebrand disease prophylaxis network